Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials
Chiu HY, Yeh TH, Huang YC, Chen PY
Published in Pain Physician
Methodology
Meta-analysis of 21 RCTs: 11 of intravenous magnesium for acute migraine (948 participants) and 10 of oral magnesium for prophylaxis (789 participants).
Key Findings
Intravenous magnesium relieved acute attacks at 15-45 minutes, 120 minutes and 24 hours (ORs 0.23, 0.20, 0.25); oral magnesium reduced migraine frequency and intensity (ORs 0.20 and 0.27).
Conclusions
Oral magnesium reduces headache frequency and intensity and intravenous magnesium helps acute attacks, supporting magnesium as part of a multimodal approach.
Limitations
Some included trials used inadequate randomization, heterogeneous dosing and formulations, and publication bias cannot be excluded.
Supplements Studied
Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27).
Outcomes Measured
Oral magnesium significantly alleviated the frequency and intensity of migraine.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not stated
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.